Matrine Injection Influences Serum IL-2,CD4~+,CD4~+/CD8~+ And Tumormarkers Levels Of The Patients With Advanced Gastrointestinal Tumors

Objective:1.Observe the influences of matrine injection on the immune effects of tumor patients By studying IL-2, blood CD4, CD4/CD8 level matrine injection acted on the serum of patients with advanced gastrointestinal tumors.2. Assessment of matrine injection treatment By observing the levels of tumor marker.Methods:60 cases of advanced gastrointestinal tumors cancer patients (IV period), Exclude infection, autoimmune disease, diabetes, severe organ dysfunction and other disease patients, while excluding other gastrointestinal tumors; non-surgical application,no radiotherapy and chemotherapy and immunosuppressive agents; No serious trauma and physical disease. Randomly divided into two groups:①control group:Nutritional the experimental support, pain and other symptomatic treatment, treatment time was 10 days.②The group:20ml matrine injection mixed in 250ml 5% glucose intravenous injection to treat Patients,and other nutritional support and treatment, treatment time was 10 days. Take 3ml venous blood before and after treatment. One of the stand in room temperature for 20min,3000r/min centrifugal, and keep in-75℃refrigerator. Measured concentration of IL-2 by ELISA. Save it in a tube with EDTA reagent, and immediately sent to the central laboratory, Measured CD4, CD4/CD8 ratio by flow cytometry. Another are sent to the laboratory and Measured tumor markers in families.Result:1.The control group levels of interleukin-2 before and after treatment have no significant difference (P>0.05).The experimental group data before treatment(14.505+1.071 pg/ml), data (25.917+1.914 pg/ml), both compared to the number after treatment were significantly greater than before treatment (P<0.05). Experimental group and control group (P<0.05), were significantly different. That matrine injection can improve patients with advanced gastrointestinal cancer interleukin-2 levels.2. Two groups of patients before treatment, CD4+, CD4+/CD8+ratio were lower than normal, while the CD8+high. In the control group before and after the CD4+, CD8+, CD4+/CD8+ratio comparison, P> 0.05, no statistical significance between the two groups. The treatment group of CD4+, CD4+/CD8+ratio increased, CD8+decreased, P<0.05, before and after treatment were significantly different. Between two groups, P<0.05, statistically significant. That matrine injection in patients after treatment can increase CD4+, CD4+/CD8+ratio level. However, CD4+levels are still below normal, may be related to drug short time.3. In control group, the positive rate of CEA before and after treatment were 50%, CA19-9 positive rates were 53.3% and 50%. In experimental group, the positive rate of CEA before and after treatment were 53.3% and 50%, CA19-9 positive rates were 56.7%.Between two groups or before and after treatment, all P> 0.05.The rate of CEA, CA19-9 value 50% reduce, the control group were 20% and 16.7%; the experimental group were 46.7% and 50%. Between the two groups, P<0.05, statistically significant.Conclusion:1. Matrine injection in patients with advanced gastrointestinal tumors can increase serum levels of interleukin 2 levels and improve the patients immune system, has anti-tumor effect.2. Matrine injection can improve the patients CD4+, CD4+/CD8+ratio levels and lower levels of CD8+, CD4+levels but still below normal, may be related to the short treatment time.3. Matrine injection in patients with advanced gastrointestinal tumors can not be reduced CEA and CA19-9 positive rate, but can effectively reduce the CEA and CA19-9 level.